City College & MSK Partnership for Cancer Care and Community Outreach
Official title: 1/2 CCNY-MSK Partnership for Cancer Research, Education and Community Outreach
Funded at City College of New York · NIH-11194430 · Data updated 2026-11-12
This partnership develops new cancer treatments, tests ways to reduce treatment side effects and help patients keep appointments, uses AI-powered medical interpreting, and builds community education for people affected by cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | City College of New York NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 26, 2008 |
| Project end | August 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $1,334,500 |
| NIH project number | 5U54CA132378-17 |
| Project ID | NIH-11194430 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal participants include people with cancer treated at MSK or affiliated clinics—particularly those on immune checkpoint inhibitors, people with lung cancer, and patients who need medical interpreting services.
✕Less likely to help
Patients with cancers not covered by the partnership projects or those far from New York City may not directly benefit from or be eligible for participation.
What this research studies
This collaboration brings together City College of New York and Memorial Sloan Kettering to move lab discoveries toward real-world cancer care while training students and working with local communities. Projects include helping people on immune checkpoint inhibitors manage side effects and stay on treatment, searching for small molecules that target cancer-driving proteins, testing AI-enhanced medical interpreting to improve communication, and studying germline factors that shape lung tumor genomes. Work spans laboratory experiments, clinic-based patient studies, and community outreach programs. You might be asked to participate in symptom-management interventions, provide clinical samples, or take part in communication/interpretation testing.
Why it matters
Potential benefit: If successful, this work could reduce treatment side effects, improve attendance and communication during care, and lead to more targeted therapies for some cancers.
How similar studies have gone: Aspects build on prior successes—immunotherapy symptom-management and targeted small-molecule approaches have shown promise, while AI-driven medical interpreting and germline-informed tumor profiling are newer but rapidly developing areas.
Where this research is happening
-
City College of New York
New York, United States Active
Researchers
- Principal investigator: Vuong, Bao Q — City College of New York
- Study coordinator: Vuong, Bao Q
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.